Analysts at Rodman & Renshaw began coverage on shares of CytoDyn Inc. (OTC:CYDY) in a research report issued on Thursday, reports. The firm set a “buy” rating and a $1.60 price target on the stock. Rodman & Renshaw’s price target points to a potential upside of 125.35% from the company’s previous close.

CytoDyn (OTC:CYDY) opened at 0.71 on Thursday. CytoDyn has a one year low of $0.63 and a one year high of $1.57. The stock’s 50 day moving average price is $0.87 and its 200 day moving average price is $1.04. The company’s market capitalization is $88.42 million.

About CytoDyn

CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.

Stock Target Prices

Receive News & Ratings for CytoDyn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc. and related companies with's FREE daily email newsletter.